-
EP1301201
European procedure
Extract from the Register of European Patents
EP About this file: EP1301201
| EP1301201 - TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II [Right-click to bookmark this link] | Status | Patent revoked Status updated on 30.11.2018 Database last updated on 29.03.2025 | Most recent event Tooltip | 30.11.2018 | Revocation of patent | published on 02.01.2019 [2019/01] | Applicant(s) | For all designated states Duke University Durham North Carolina 27710 / US | [2007/09] |
| Former [2003/16] | For all designated states DUKE UNIVERSITY Durham, North Carolina 27710 / US | Inventor(s) | 01 /
CHEN, Yuan-Tsong 1066 Canterbury Lane Chapel Hill, NC 27514 / US | [2003/16] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [N/P] |
| Former [2010/35] | Jaenichen, Hans-Rainer, et al Vossius & Partner Postfach 86 07 67 81634 München / DE | ||
| Former [2004/31] | Kirkham, Nicholas Andrew, et al Graham Watt & Co LLP St Botolph's House 7-9 St Botolph's Road Sevenoaks Kent TN13 3AJ / GB | ||
| Former [2003/16] | Holdcroft, James Gerald, Dr., et al Graham Watt & Co. St. Botolph's House 7-9 St. Botolph's Road Sevenoaks, Kent TN13 3AJ / GB | Application number, filing date | 01951000.7 | 10.07.2001 | [2003/16] | WO2001US21651 | Priority number, date | US20000219237P | 18.07.2000 Original published format: US 219237 P | [2003/16] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO0205841 | Date: | 24.01.2002 | Language: | EN | [2002/04] | Type: | A1 Application with search report | No.: | EP1301201 | Date: | 16.04.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.01.2002 takes the place of the publication of the European patent application. | [2003/16] | Type: | B1 Patent specification | No.: | EP1301201 | Date: | 28.02.2007 | Language: | EN | [2007/09] | Search report(s) | International search report - published on: | EP | 24.01.2002 | Classification | IPC: | A61K38/47, A61P21/00 | [2003/16] | CPC: |
A61K38/47 (EP,US);
A61K45/06 (US);
A61P21/00 (EP);
A61P3/00 (EP);
A61P3/10 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/02 (EP);
| C-Set: |
A61K38/47, A61K2300/00 (EP,US)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/16] | Extension states | AL | 05.02.2003 | LT | 05.02.2003 | LV | 05.02.2003 | MK | 05.02.2003 | RO | 05.02.2003 | SI | 05.02.2003 | Title | German: | BEHANDLUNG DER GLYKOGENSPEICHERKRANKHEIT TYP II | [2003/16] | English: | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II | [2003/16] | French: | TRAITEMENT DE LA GLYCOGENOSE DE TYPE II | [2003/16] | Entry into regional phase | 05.02.2003 | National basic fee paid | 05.02.2003 | Designation fee(s) paid | 05.02.2003 | Examination fee paid | Examination procedure | 25.01.2002 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 03.02.2003 | Amendment by applicant (claims and/or description) | 05.02.2003 | Examination requested [2003/16] | 18.07.2005 | Despatch of a communication from the examining division (Time limit: M08) | 28.03.2006 | Reply to a communication from the examining division | 11.04.2006 | Despatch of a communication from the examining division (Time limit: M04) | 21.08.2006 | Reply to a communication from the examining division | 27.10.2006 | Communication of intention to grant the patent | 17.01.2007 | Fee for grant paid | 17.01.2007 | Fee for publishing/printing paid | Divisional application(s) | EP07001091.3 / EP1782825 | EP14167882.1 / EP2767291 | EP16178390.7 / EP3108895 | EP18194771.4 / EP3449934 | Opposition(s) | Opponent(s) | 01
22.11.2007
ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP Unit A, Faraday Court Faraday Road Crawley, West Sussex RH10 9PU / GB | [N/P] |
| Former [2008/02] | |||
| Opponent(s) | 01
22.11.2007
ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP The Gables Massetts Road Horley Surrey RH6 7DQ / GB | 10.01.2008 | Invitation to proprietor to file observations on the notice of opposition | 22.09.2008 | Reply of patent proprietor to notice(s) of opposition | 14.12.2012 | Date of oral proceedings | 01.02.2013 | Despatch of minutes of oral proceedings | 01.02.2013 | Despatch of communication that the patent will be revoked | 06.03.2018 | Legal effect of revocation of patent [2019/01] | Appeal following opposition | 09.04.2013 | Appeal received No. T0867/13 | 10.06.2013 | Statement of grounds filed | 06.03.2018 | Result of appeal procedure: appeal of the proprietor was rejected | 06.03.2018 | Date of oral proceedings | 19.03.2018 | Minutes of the oral proceedings despatched | Fees paid | Renewal fee | 14.07.2003 | Renewal fee patent year 03 | 14.07.2004 | Renewal fee patent year 04 | 20.07.2005 | Renewal fee patent year 05 | 10.07.2006 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CY | 28.02.2007 | MC | 31.07.2007 | [2009/33] |
| Former [2008/22] | MC | 31.07.2007 | Cited in | International search | [X]WO0034451 (PHARMING INTELLECTUAL PTY BV [NL], et al) [X] 1-5,7,8,10-14,16,17 * the whole document *; | [XP]US6118045 (REUSER ARNOLD J J [NL], et al) [XP] 1,3,5,8,10,11,14 * claim 18 *; | [X] - BARSY DE T ET AL, "ENZYME REPLACEMENT IN POMPE DISEASE: AN ATTEMPT WITH PURIFIED HUMAN ACID ALPHA-GLUCOSIDASE", BIRTH DEFECTS ORIGINAL ARTICLE SERIES, LISS, NEW YORK, NY,, US, (197303), vol. 9, no. 2, ISSN 0547-6844, pages 184 - 190, XP002922372 [X] 1,3,4,8,10,11,13,17 * the whole document * | [X] - YANG HELEN WEN ET AL, "Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.", PEDIATRIC RESEARCH, (199803), vol. 43, no. 3, ISSN 0031-3998, pages 374 - 380, XP001041466 [X] 1,3,5,6,10,11,14,15 * the whole document * | [X] - BYRNE BARRY J ET AL, "Reconstitution of acid alpha-glucosidase activity in a mouse model of cardioskeletal myopathy, Pompe's disease.", CIRCULATION, 71st Scientific Sessions of the American Heart Association;Dallas, Texas, USA; November 8-11, 1998, (19981027), vol. 98, no. 17 SUPPL., ISSN 0009-7322, page I737, XP001041662 [X] 1-3,5,8,10-12,14,17 * the whole document * | [T] - AMALFITANO ANDREA ET AL, "Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial.", GENETICS IN MEDICINE, (200103), vol. 3, no. 2, ISSN 1098-3600, pages 132 - 138, XP002184189 [T] 1-8,10-17 * the whole document * DOI: http://dx.doi.org/10.1097/00125817-200103000-00008 | Examination | - PLOEG ET AL, JOURNAL OF CLINICAL INVESTIGATIONS, (1991), vol. 87, pages 513 - 518 |